Aspartic acid scaffold in bradykinin B1 antagonists

Journal of Peptide Science

Volumn 15, Issue 6, 2009, Pages 423-434

  Huszár, József ^a   Timár, Zoltán ^a   Bogár, Ferenc ^a   Penke, Botond ^a   Kiss, Róbert ^b   Szalai, Krisztina Katalin ^b   Schmidt, Éva ^b   Papp, Andrea ^b   Keserü, György ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b GEDEON RICHTER LTD   (Hungary)

Author keywords

B1 antagonists; Binding modes; Bradykinin; Docking; Peptidomimetic

Indexed keywords

1 N CYCLOHEXYL 4 N [2 [4 (4,5 DHYDRO 1H IMIDAZOLE 2 YL)PHENYL]ETHYL] 2 (TOLUENE 4 SULFONYLAMINO)SUCCINAMIDE; ASPARTIC ACID; BRADYKININ B1 RECEPTOR ANTAGONIST; N (4 AMINO BUTYL) 2 (TOLUENE 4 SULFONYLAMINO)SUCCINAMIC ACID CYCLOHEXYL ESTER; N (4 GUANIDINO BUTYL) 2 (TOLUENE 4 SULFONYLAMINO)SUCCINAMIC ACID BENZYL ESTER; N (4 GUANIDINO BUTYL) 2 (TOLUENE 4 SULFONYLAMINO)SUCCINAMIC ACID CYCLOHEXYL ESTER; N (6 AMINO HEXYL) 2 (TOLUENE 4 SULFONYLAMINO)SUCCINAMIC ACID CYLOHEXYL ESTER; N (7 AMINO HEPTYL) 3 (TOLUENE 4 SULFONYLAMINO)SUCCINAMIC ACID CYCLOHEXYL ESTER; N [2 [4 (4,5 DIHYDRO 1H IMIDAZOL 2 YL)PHENYL]ETHYL] 2 (TOLUENE 4 SULFONYLAMINO)SUCCINAMIC ACID BENZYL ESTER; N [2 [4 (4,5 DIHYDRO 1H IMIDAZOL 2 YL)PHENYL]ETHYL] 3 (TOLUENE 4 SULFONYLAMINO)SUCCINAMIC ACID BENZYL ESTER; N [2 [4 (4,5 DIHYDRO 1H IMIDAZOL 2 YL)PHENYL]ETHYL] 3 (TOLUENE 4 SULFONYLAMINO)SUCCINAMIC ACID CYCLOHEXYL ESTER; UNCLASSIFIED DRUG; BRADYKININ B1 RECEPTOR; DRUG DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CHO CELL; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG ANTAGONISM; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN SECONDARY STRUCTURE; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ASPARTIC ACID; COMPUTER SIMULATION; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROTEIN STRUCTURE, SECONDARY; RECEPTOR, BRADYKININ B1; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 67649784853     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1134     Document Type: Article

References (40)

1. 1 receptor based on a 2-alkylamino-5-sulfamoylbenzamide core. J. Med. Chem. 2004; 47: 4642-4644.
2. Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors inpain and inflammation. Eur. J. Pharmacol. 2001; 429: 161-176.
3. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 1992; 44: 1-80.
4. 2 receptor antagonists. J. Med. Chem. 2002; 45: 2160-2172.
5. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 1980; 32: 1-46.
6. Farmer SG. In The Kinin System. Academic Press: London, 1997.
7. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000; 289: 739-745.
8. Rasmussen SGF, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, Schertler GF, Weis WI, Kobilka BK. Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 2007; 450: 383-387.
9. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-resolution crystal structure of an engineered human β2-adrenergic G protein coupled receptor. Science 2007; 318: 1258-1265.
10. 1 Receptors for Kinins. Pharmacol. Rev. 1998; 50: 357-386.
11. 1 in human lung fibroblast. Mol. Pharmacol. 1999; 56: 325-333.
12. Rashid MH, Inoue M, Matsumoto M, Ueda H. Switching of bradykinin-mediated nociception following partial sciatic nerve injury in mice. J. Pharmacol. Exp. Ther. 2004; 308: 1158-1164.
13. 1 kinin receptor activity in pigs is associated with pre-existing infection. Immunopharmacology 1998; 40: 49-55.
14. 1 receptor upregulation in a mouse model of colitis. Br. J. Pharmacol. 2008; 154: 1276-1286.
15. 2R receptors in human inflammatory bowel disease. Am. J. Physiol.Gastrointest. Liver Physiol. 2005; 289: 361-366.
16. 1 receptor and inflammation: new therapeutic target for cardiovascular disease. accepted in Curr. Opin. Pharmacol. 2009; (in press). DOI:10.1016/j.coph.2008.11.011.
17. Belichard P, Landry M, Faye P, Bachvarov DR, Bouthillier J, Pruneau D, Marceau F. Inflammatory hyperalgesia induced by zymosan in the plantar tissue of the rat: effect of kinin receptor antagonists. Immunopharmacology 2000; 46: 139-147.
18. 2 receptor on nociception in rats and mice. Pain 1997; 71: 89-97.
19. Regoli D, Allogho SN, Rizzi A, Gobeil FJ. Bradykinin receptors and their antagonists Eur. J. Pharmacol. 1998; 348: 1-10.
20. Stewart JM, Gera L, York EJ, Chan DC, Whalley EJ, Bunn PA, Vavrek R. Metabolism-resistant bradykinin antagonists: development and applications. Biol. Chem. 2001; 382: 37-41.
21. Regoli D, Barabe J, Park WK. Receptors for bradykinin in rabbit aortae. Can. J. Physiol. Pharmacol. 1977; 55: 855-867.
22. Pellegrini M, Tancredi M, Ravero P, Mierke DF. Probing the topological arrangement of the N- and C-terminal residues of bradykinin for agonist activity at the B1 receptor. J. Med. Chem. 1999; 42: 3369-3377.
23. 1 receptor antagonist. J. Am. Chem. Soc. 2003; 125: 7516-7517.
24. Amblard M, Daffix I, Bedos P, Berge G, Pruneau D, Paquet J-L, Luccarini J-M, Be'lichard P, Dodey P, Martinez J. Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety. J. Med. Chem. 1999; 42: 4185-4192.
25. Bock MG, Hess JF, Pettibone DJ. Chapter 12. Bradykinin-1 receptor antagonists. Annu. Rep. Med. Chem. 2003; 38: 111-120.
26. Bock MG, Longmore J. Bradykinin antagonists: new opportunities. Curr. Opin. Chem. Biol. 2000; 4: 401-406.
27. 1 receptor: biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 2004; 309: 661-669.
28. 1 receptor. Immunopharmacology 1999; 43: 169-177.
29. 1 antagonists. J. Med. Chem. 2003; 46: 1803-1806.
30. 1 receptor antagonist. Eur. J. Pharmacol. 2004; 499: 77-84.
31. 1 receptor antagonists. J. Med. Chem. 2004; 47: 6439-6442.
32. 1 receptor occupancy studies. Bioorg. Med. Chem. Lett. 2004; 14: 6045-6048.
33. Ha SN, Hey PJ, Ransom RW, Harrell CM Jr, Murphy KL, Chang R, Chen TB, Su DS, Markowitz MK, Bock MG, Freidinger RM, Hess FJ. Binding modes of dihydroquinoxalinones in a homology model of bradykinin receptor 1. Biochem. Biophys. Res. Commun. 2005; 331(1): 159-166.
34. Ranganathan R. Signalling across the cell membrane. Science 2007; 318: 1253-1254.
35. Massotte D, Kieffer BL. The second extracellular loop: a damper for G protein-coupled receptors? Nat. Struct. Mol. Biol. 2005; 12: 287-288.
36. Ha SN, Hey PJ, Ransom RW, Bock MG, Su DS, Murphy KL, Chang R, Chen TB, Pettibone D, Hess JF. Identification of the critical residues of bradykinin receptor B1 for interaction with the kinins guided by site-directed mutagenesis and molecular modeling. Biochemistry 2006; 45: 14355-14361.
37. Šali A, Blundell TL. Comparative proteinmodelling by satisfaction of spatial restraints. J. Mol. Biol. 1993; 234: 779-815.
38. Hanson MA, Cherezov V, Griffith MT, Roth CB, Jaakola VP, Chien EY, Velasquez J, Kuhn P, Stevens C. A Specific cholesterol binding site is established by the 2.8 Å structure of the human beta(2)-adrenergic receptor. Structure 2008; 16: 897.
39. SYBYL 7.3, Tripos International, 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA.
40. Ballesteros, JA, Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 1995; 25: 366-428.